Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst

On Thursday, ResMed Inc (NYSE:RMD) reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04.

The company reported sales of $1.224 billion, up 11%, beating the consensus of $1.18 billion, driven by increased demand for sleep devices and masks portfolio and strong growth across the Residential Care Software business.

Residential Care Software revenue increased by 12% on a constant currency basis, reflecting continued organic growth in the Residential Care Software portfolio.

Gross margin increased by 420 basis points mainly due to manufacturing efficiencies, component cost improvements, and an increase in average selling prices. Non-GAAP gross margin increased by 320 basis.

“Our first-quarter fiscal year 2025 results reflect ongoing momentum and strong execution across all areas of our business,” ...